| Host: |
Mouse |
| Applications: |
IHC/WB |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Mouse monoclonal antibody anti-Keratin, type I cytoskeletal 13 (400-458 aa) is suitable for use in Immunohistochemistry and Western Blot research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
ABT057 |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG1k |
| Formulation: |
Liquid in PBS pH7.2, 0.03% Proclin 300, with stabilizing protein. |
| Purification: |
The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. |
| Dilution Range: |
IHC-P 1:200-400WB 500-1000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
KRT13 |
| Gene ID: |
3860 |
| Uniprot ID: |
K1C13_HUMAN |
| Immunogen Region: |
400-458 aa |
| Specificity: |
The antibody can specifically recognize human CK13 protein. In western blotting of A431 cell lysate, the antibody can label a 50 kDa band corresponding to CK13. |
| Immunogen: |
Synthesized peptide derived from the human Cytokeratin 13 at the amino acid range 400-458 |
| Post Translational Modifications | O-glycosylated.glycans consist of single N-acetylglucosamine residues. |
| Function | Type 1 keratin (Probable). Maintains postnatal tongue mucosal cell homeostasis and tissue organization in response to mechanical stress, potentially via regulation of the G1/S phase cyclins CCNE1 and CCNE2. |
| Protein Name | Keratin - Type I Cytoskeletal 13Cytokeratin-13Ck-13Keratin-13K13 |
| Database Links | Reactome: R-HSA-6805567Reactome: R-HSA-6809371 |
| Alternative Antibody Names | Anti-Keratin - Type I Cytoskeletal 13 antibodyAnti-Cytokeratin-13 antibodyAnti-Ck-13 antibodyAnti-Keratin-13 antibodyAnti-K13 antibodyAnti-KRT13 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
